1287585-40-3
1287585-40-3 结构式
基本信息
N-acetyl lysyltyrosylcysteine amide(Myeloperoxidase inhibitor KYC)
物理化学性质
常见问题列表
N-Acetyl lysyltyrosylcysteine amide (KYC) significantly decreases infarct size, blood-brain barrier leakage, infiltration of myeloid cells, loss of neurons, and apoptosis in the brains of middle cerebral artery occlusion (MCAO) mice.
N-Acetyl lysyltyrosylcysteine amide (10 mg/kg; i.p.; daily for 3-7 days) significantly reduces neurological severity scores and infarct size in MCAO mice.
N-Acetyl lysyltyrosylcysteine amide (10 mg/kg; i.p.; daily 7 days) significantly protects BBB function and decreased neutrophil infiltration. N-Acetyl lysyltyrosylcysteine amide (10 mg/kg; i.p.; daily 7 days) significantly reduces microglia/macrophage activation and neuron loss in MCAO mice. N-Acetyl lysyltyrosylcysteine amide (10 mg/kg; i.p.; daily for 3-7 days) decreases apoptosis and cell injury in the brains of MCAO mice. N-Acetyl lysyltyrosylcysteine amide reduced MPO in the brains of MCAO mice. N-Acetyl lysyltyrosylcysteine amide reduces NO2Tyr and 4-HNE in MCAO mice.
| Animal Model: | 8-10 weeks old C57BL/6J mice (middle cerebral artery occlusion (MCAO) mode) |
| Dosage: | 10 mg/kg |
| Administration: | I.p.; daily for 3-7 days |
| Result: | Significantly reduced neurological deficit and brain infarct size in mice subjected to MCAO. |